Cytokinetics Future Growth
Future criteria checks 2/6
Cytokinetics is forecast to grow earnings and revenue by 44.9% and 59.5% per annum respectively while EPS is expected to grow by 46.8% per annum.
Key information
44.9%
Earnings growth rate
46.8%
EPS growth rate
Biotechs earnings growth | 24.6% |
Revenue growth rate | 59.5% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | 10 Jun 2024 |
Recent future growth updates
Recent updates
Cytokinetics Decides To Go It Alone
May 24Here's Why We Think Cytokinetics, Incorporated's (NASDAQ:CYTK) CEO Compensation Looks Fair for the time being
May 09Cytokinetics, Incorporated: Buyout Speculation Persists
Apr 01Cytokinetics: CEO Talks Down Buyout Prospects
Mar 16Cytokinetics Steps Up As Prime Target After Aficamten's HCM Triumph (Rating Upgrade)
Jan 12An Intrinsic Calculation For Cytokinetics, Incorporated (NASDAQ:CYTK) Suggests It's 37% Undervalued
Oct 05Analysts Are Betting On Cytokinetics, Incorporated (NASDAQ:CYTK) With A Big Upgrade This Week
May 07Analysts Are Betting On Cytokinetics, Incorporated (NASDAQ:CYTK) With A Big Upgrade This Week
Mar 03Cytokinetics, Incorporated's (NASDAQ:CYTK) Intrinsic Value Is Potentially 100% Above Its Share Price
Jan 20Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 388 | -309 | -117 | -362 | 12 |
12/31/2025 | 75 | -489 | -494 | -464 | 16 |
12/31/2024 | 29 | -492 | -457 | -411 | 17 |
3/31/2024 | 4 | -531 | -423 | -422 | N/A |
12/31/2023 | 8 | -526 | -416 | -414 | N/A |
9/30/2023 | 8 | -527 | -443 | -438 | N/A |
6/30/2023 | 10 | -540 | -437 | -426 | N/A |
3/31/2023 | 98 | -431 | -406 | -395 | N/A |
12/31/2022 | 95 | -389 | -311 | -300 | N/A |
9/30/2022 | 148 | -282 | -272 | -246 | N/A |
6/30/2022 | 151 | -216 | -236 | -201 | N/A |
3/31/2022 | 65 | -258 | -183 | -140 | N/A |
12/31/2021 | 70 | -215 | -191 | -143 | N/A |
9/30/2021 | 22 | -229 | -83 | -46 | N/A |
6/30/2021 | 58 | -156 | -17 | 8 | N/A |
3/31/2021 | 59 | -135 | -7 | 10 | N/A |
12/31/2020 | 56 | -127 | -2 | 9 | N/A |
9/30/2020 | 54 | -114 | -68 | -62 | N/A |
6/30/2020 | 19 | -140 | -101 | -97 | N/A |
3/31/2020 | 22 | -132 | -98 | -94 | N/A |
12/31/2019 | 27 | -122 | -94 | -91 | N/A |
9/30/2019 | 31 | -118 | -86 | -84 | N/A |
6/30/2019 | 36 | -110 | -97 | -96 | N/A |
3/31/2019 | 35 | -105 | -99 | -98 | N/A |
12/31/2018 | 32 | -106 | -102 | -101 | N/A |
9/30/2018 | 22 | -120 | -114 | -113 | N/A |
6/30/2018 | 18 | -131 | -108 | -106 | N/A |
3/31/2018 | 14 | -132 | -112 | -111 | N/A |
12/31/2017 | 13 | -128 | N/A | -102 | N/A |
9/30/2017 | 47 | -80 | N/A | 0 | N/A |
6/30/2017 | 99 | -14 | N/A | 14 | N/A |
3/31/2017 | 102 | 3 | N/A | 34 | N/A |
12/31/2016 | 106 | 16 | N/A | 37 | N/A |
9/30/2016 | 83 | 0 | N/A | -51 | N/A |
6/30/2016 | 32 | -42 | N/A | -49 | N/A |
3/31/2016 | 33 | -41 | N/A | -47 | N/A |
12/31/2015 | 29 | -38 | N/A | 5 | N/A |
9/30/2015 | 41 | -20 | N/A | 7 | N/A |
6/30/2015 | 42 | -17 | N/A | 8 | N/A |
3/31/2015 | 43 | -15 | N/A | 7 | N/A |
12/31/2014 | 47 | -15 | N/A | -45 | N/A |
9/30/2014 | 50 | -17 | N/A | -49 | N/A |
6/30/2014 | 45 | -23 | N/A | -29 | N/A |
3/31/2014 | 38 | -30 | N/A | -13 | N/A |
12/31/2013 | 31 | -34 | N/A | -8 | N/A |
9/30/2013 | 8 | -52 | N/A | -2 | N/A |
6/30/2013 | 6 | -49 | N/A | -22 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CYTK is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CYTK is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CYTK is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CYTK's revenue (59.5% per year) is forecast to grow faster than the US market (8.4% per year).
High Growth Revenue: CYTK's revenue (59.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CYTK's Return on Equity is forecast to be high in 3 years time